Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2019.431 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2007.098 | A Phase 3 Randomized Trial of Chemotherapy With or Without Panitumumab in Patients with Metastatic and/or Recurrent Squamous Cell Carcinoma of the Heart and Neck | Prof. Chan Anthony |
| 2020.088 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 |
Dr. HUI David Shu Cheong 許樹昌 |
| 2020.089 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment |
Dr. HUI David Shu Cheong 許樹昌 |
| 2006.201 | A Phase 3 Randomized Study to Evaluate Survival of Patients Treated with Talaporfin Sodium (LS11) and Interstitial Light Emitting Diodes (LED) as Compared to the Standard of Care Therapies in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | Prof. Mok Tony |
| 2019.166 | A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma |
Prof. NG Chi Fai 吳志輝 |
| 2014.364 | A Phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pediatric patients with severe hemophilia A | Dr. LI Chi Kong |
| 2024.269 | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. | Dr. LOONG Herbert Ho Fung |
| 2015.580 | A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
| 2020.156 | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2013.658 | A PHASE 3 DOUNLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDMIA AT RISK OF CARDIOVASCULAR EVENTS | Prof. YAN Bryan Ping Yen |
| 2019.150 | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) |
Dr. CHAN Stephen L. 陳林醫生 |
| 2011.263 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SAFETY AND EFFICACY STUDY OF ONCE DAILY CONTROLLED RELEASE PREGABALIN IN THE TREATMENT OF PATIENTS WITH POSTHERPETIC NEURALGIA | Prof. GIN Tony |
| 2013.604 | A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS | Dr. SO Wing Yee |
| 2009.528 | A Phase 2B, Randomized, Double-blind, Placebo-Controlled, Dose Ranging Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Moderate to Severe Pain Associated with Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) | Dr. Ng Chi Fai |
| 2009.526 | A Phase 2B, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of tanezumab for the treatment of moderate to severe pain associated with interstitial cystitis / painful bladder syndrome (IC/PBS) | Dr. Chan Shing Chee |
| 2015.635 | A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection |
Prof. LEE Nelson Lai Shun 李禮舜 |
| 2023.151 | A phase 2b, open-label study to evaluate the efficacy, safety, tolerability, immunogenicity and treatment regimens of VTP-300 combined with low-dose nivolumab in Chronic Hepatitis B Infection |
Prof. WONG Grace Lai Hung Grace LH Wong |
| 2023.260 | A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke who are not eligible for tissue plasminogen activator or thrombectomy | Prof. LEUNG Thomas Wai Hong |
| 2023.182 | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of HTD1801 in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis who Have Type 2 Diabetes or Pre-Diabetes (The CENTRICITY Study) | Prof. WONG Vincent Wai Sun |
| 2019.415 | A Phase 2b, Multicenter, Double-blind, Active Controlled, Randomized Study to Investigate the Efficacy and Safety of different combination regimens including JNJ-73763989 and/or JNJ-56136379 for the treatment of Chronic Hepatitis B Virus Infection | Prof. WONG Vincent Wai Sun |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2023.249 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults With Precirrhotic Nonalcoholic Steatohepatitis | Prof. WONG Vincent Wai Sun |
| 2020.602 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis |
Prof. WONG Vincent Wai Sun 黃煒燊教授 |
| 2020.557 | A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis | Prof. KONG Alice Pik Shan |
| 2018.104 | A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2009.429 | A Phase 2A, Randomized, Double-Blind, Active and Placebo-Controlled Study of PF-04171327 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis | Dr. TAM Lai-Shan |
| 2022.656 | A Phase 2a, Randomized, Blinded, Multicenter Study Investigating a Combination of AB-729 and VTP-300 in Virologically-Suppressed Chronic Hepatitis B Participants | Prof. WONG Grace Lai Hung |
| 2021.427 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
Prof. WONG Grace Lai Hung 黃麗虹教授 |
| 2021.402 | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) | Dr. YIP Wai Man |
| 2024.002 | A Phase 2a, Open-Label Multiple Dose Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Imdusiran (AB-729) in Combination with Intermittent Dosing of Durvalumab, a PD-L1 Monoclonal Antibody, in Subjects with Chronic HBV Infection | Prof. Wong Grace Lai Hung |
| 2020.509 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection |
Prof Wong Grace Lai Hung 黃麗虹 |
| 2020.310 | A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification with ABI-H0731 in Subjects with Chronic Hepatitis B Infection on Nucleos(t)ide Reverse Transcriptase Inhibitors | Prof. WONG Grace Lai Hung |
| 2008.100 | A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atacicept in Subjects with Lupus Nephritis in Combination with Mycophenolate Mofetil Therapy | Prof. Szeto Cheuk Chun |
| 2003.088 | A Phase 2/3, Multicenter, Randomized, Controlled, Open-Label Study of Intravenous T138067-Sodium versus Intravenous Doxorubicin in Subjects with Chemotherapy-Na_ve, Unresectable Hepatocellular Carcinoma | Prof. Mok SK Tony |
| 2013.296 | A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A | Dr. Wong Siu Ming Raymond |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2002.231 | A Phase 2/3 Open Label Multicenter Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients with Unresectable Hepatocellular Carcinoma( Revised : CRE-2002.150-T) | Prof. Mok Tony |
| 2022.448 | A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema |
Prof. CHEN Guy Lijia 陳理佳 |
| 2015.579 | A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2021.147 | A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
Prof. POON Wai Sang 潘偉生 |
| 2007.307 | A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects with Non-Valvular Atrial Fibrillation | Prof. Yu Cheuk Man |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2018.344 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Dr. AU Kenneth Hon Da 許祖紳醫生 |
| 2021.154 | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073) |
Dr. CHAN Stephen Lam 陳林 |
| 2018.472 | A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer (CheckMate 9UT: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9UT) |
Dr. POON Darren Ming Chun 潘明駿 |
| 2009.163 | A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics and Biological Effects of Intravenous Fosbretabulin in Asian Subjects with Polypoidal Choroidal Vasculopathy (PCV) | Dr Lai Timothy Yuk Yau |
| 2012.134 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
Page 237 of 254.